Kelleher Financial Advisors Has $4.41 Million Holdings in AbbVie Inc. $ABBV

Kelleher Financial Advisors grew its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 50.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 17,508 shares of the company's stock after buying an additional 5,868 shares during the period. Kelleher Financial Advisors' holdings in AbbVie were worth $4,406,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Litman Gregory Wealth Management LLC acquired a new position in shares of AbbVie during the 4th quarter valued at $28,000. Imprint Wealth LLC grew its holdings in AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company's stock worth $29,000 after purchasing an additional 45 shares during the period. Legacy Wealth Managment LLC ID increased its stake in AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock valued at $31,000 after purchasing an additional 73 shares in the last quarter. IFC & Insurance Marketing Inc. acquired a new position in shares of AbbVie during the fourth quarter valued at about $31,000. Finally, Abound Financial LLC acquired a new position in shares of AbbVie during the fourth quarter valued at about $32,000. Institutional investors and hedge funds own 70.23% of the company's stock.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is owned by corporate insiders.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $265.56 on Wednesday. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The stock has a market cap of $469.18 billion, a price-to-earnings ratio of 75.02, a PEG ratio of 0.88 and a beta of 0.30. The firm's 50-day simple moving average is $250.20 and its 200 day simple moving average is $228.12.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company's revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 14.06 EPS for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's dividend payout ratio is presently 195.48%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Humira replacement strategy is gaining credibility: second-quarter revenue rose 10.2% to $16.99 billion, led by immunology products and supported by neuroscience. This suggests Skyrizi, Rinvoq and other newer medicines are more than offsetting Humira’s biosimilar-related decline. AbbVie’s Humira Replacement Strategy Is Working
• Positive Sentiment: New lung-cancer data for investigational treatments ABBV-1480, ABBV-706 and Temab-A point to potentially meaningful future growth in oncology. Reported response rates and manageable safety profiles strengthen the case for AbbVie’s longer-term pipeline, though the programs remain dependent on additional clinical results and approvals. Is AbbVie Quietly Rebalancing Its Growth Story Around Oncology Innovation?
• Positive Sentiment: Several investment managers increased their AbbVie holdings, including Convergence Financial, which nearly doubled its position, and Donaldson Capital Management, which modestly raised its stake. These filings provide a supportive institutional signal but are not major earnings catalysts. Convergence Financial Increased Its AbbVie Holdings
• Neutral Sentiment: In comparisons with Eli Lilly, AbbVie offers a more established cash-generating portfolio and attractive pipeline opportunities, while Lilly has stronger headline growth prospects. The debate highlights AbbVie’s balance between income, stability and pipeline execution rather than a clear near-term catalyst. LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?
• Negative Sentiment: Second-quarter oncology sales declined 2.4% as Imbruvica continued to weaken. Growth from Venclexta and newer medicines partly offset the pressure, but the result underscores ongoing reliance on successful launches and pipeline products to revive the franchise. How Did AbbVie’s Oncology Sales Hold Up in Q2?

Analysts Set New Price Targets

ABBV has been the subject of several research reports. Guggenheim raised their target price on AbbVie from $261.00 to $288.00 and gave the company a "buy" rating in a research note on Tuesday, August 4th. BMO Capital Markets increased their price target on AbbVie from $258.00 to $300.00 and gave the stock an "outperform" rating in a report on Monday, July 13th. Wells Fargo & Company raised their price objective on AbbVie from $295.00 to $300.00 and gave the company an "overweight" rating in a research note on Monday, August 17th. UBS Group boosted their price objective on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a report on Monday, July 13th. Finally, Evercore set a $235.00 target price on AbbVie in a research report on Friday, May 15th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $275.95.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source